三诺生物：接受华安证券等投资者调研

Group 1 - The core point of the article is that Sanofi Biologics (SZ 300298) announced an investor meeting on October 24, 2025, where the company's vice president and board secretary, Zheng Jiyun, participated in addressing investor inquiries [1] - For the first half of 2025, Sanofi Biologics reported that 99.66% of its revenue came from medical devices, while other sources contributed only 0.34% [1] - As of the report date, Sanofi Biologics has a market capitalization of 10.7 billion yuan [1] Group 2 - The article also highlights that the Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year, indicating a robust secondary market for biomedicine [1] - A conversation with Lu Gang, a partner at Chuangdong Investment, points out the contrast between the hot secondary market and the cooling fundraising environment in the primary market for biomedicine [1]